Biohaven presented new data on its MoDE and TRAP degrader platforms for Graves’ disease, including Phase 3 trial progress for BHV-1300, detailed Phase 1b biomarker results, and preclinical findings for BHV-1440, alongside a regional MoDE licensing deal with Ono Pharmaceutical announced in October 2026.
